Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...
HONG KONG, March 18, 2026 /PRNewswire/ -- Organised by the Hong Kong Trade Development Council (HKTDC), MarketingPulse and eTailingPulse – Asia's premier annual e-commerce and marketing events – will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results